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Abstract
Background: Scientific research on palliative care in dementia is still underdeveloped. In particular, there are no
research studies at all on palliative care issues in young onset dementia (YOD), although significant differences
compared to late onset dementia (LOD) are expected. Most studies have focused on persons with dementia in
long term care (LTC) facilities but have neglected persons that are cared for at home. We hypothesize that unmet
care needs exist in advanced and terminal stages of YOD and LOD and that they differ between YOD and LOD.
Methods/design: The EPYLOGE-study (IssuEs in Palliative care for people in advanced and terminal stages of
Young-onset and Late-Onset dementia in GErmany) aims to prospectively assess and survey 200 persons with YOD
and LOD in advanced stages who are cared for in LTC facilities and at home. Furthermore, EPYLOGE aims to investigate the
circumstances of death of 100 persons with YOD and LOD. This includes 1) describing symptoms and management, health
care utilization, palliative care provision, quality of life and death, elements of advance care planning, family caregivers’
needs and satisfaction; 2) comparing YOD and LOD regarding these factors; 3) developing expert-consensus
recommendations derived from the study results for the improvement and implementation of strategies and
interventions for palliative care provision; 4) and communicating the recommendations nationally and internationally in
order to improve and adapt guidelines, to change current practice and to give a basis and perspectives for future
research projects. The results will also be communicated to patients and their families in order to counsel and support
them in their decision making processes and their dialogue with professional caregivers and physicians.
Discussion: EPYLOGE is the first study in Germany that assesses palliative care and end-of-life issues in dementia.
Furthermore, it is the first study internationally that focuses on the specific palliative care situation of persons with YOD
and their families. EPYLOGE serves as a basis for the improvement of palliative care in dementia.
Trial registration: The study is registered in ClinicalTrials.gov (NCT03364179; Registered: 6. December 2017.
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Background
Most dementias are life-limiting disorders for which a
curative treatment does not exist. Advanced stages of
dementia are characterized by severe cognitive and phys-
ical impairment and the need for 24-h care for most pa-
tients. Therefore, at least 50% of persons with advanced
dementia are admitted into long term care (LTC) set-
tings, where they finally die if they are not transferred to
an acute hospital shortly before their death [1, 2].
It is controversial when palliative care should start during
the disease trajectory. However, it is beyond doubt that in
advanced dementia stages - when the aim of treatment is
no longer focused on stabilization of cognitive functioning
nor prolongation of life - provision of comfort-oriented
measures in order to maximize quality of life requires pal-
liative care, sometimes even specialized palliative care [3].
Worldwide – and particularly in the Netherlands and Great
Britain - several research groups have been focusing on pal-
liative care in dementia. The intersection of palliative care
and late-onset dementia (LOD) has been addressed in nu-
merous studies, e.g. the Dutch End of Life in Dementia
(DEOLD) study [4], the Implementation of quality indica-
tors in palliative care study (IMPACT) [5] and the Zürich
Life and Death with Advanced Dementia (ZULIDAD) study
[6]. These studies provide insights into the symptoms and
findings observed in advanced and terminal stages of de-
mentia, treatment options, healthcare conditions, quality of
life and death, patients’ needs, care goals, reasons and cir-
cumstances of death, end-of-life outcomes, attitudes of
nursing staff and doctors as well as the needs and problems
of relatives, formal and informal caregivers. Various instru-
ments have been validated in order to assess pain, burden,
discomfort, and quality of life (e.g. [7]) and have success-
fully been used as outcome measures [8–13].
In several countries, guidelines or recommendations
have been developed in order to improve the delivery of
palliative care for persons with dementia. As an example,
the guidelines on dementia of the British National Insti-
tute on Clinical Excellence [14] include key palliative
care components. The European Association for Pallia-
tive Care (EAPC) formulated specific recommendations
for palliative care of persons with dementia [3].
Compared to the multifaceted international efforts to
evaluate and improve palliative care strategies in demen-
tia, research initiatives and care strategies in Germany
are scarce. Initiated by the Robert-Bosch-Stiftung, a Cur-
riculum Palliative Practice for staff that works in old-age
care with persons suffering from dementia was devel-
oped. The German Society for Palliative Care has estab-
lished a standardized training of teachers for the
“Curriculum Palliative Practice”, though effects of the
training have not yet been evaluated.
A few reviews on palliative care and dementia have
been conducted by German authors [15]. One study has
investigated causes and places of death of persons with
dementia in Germany [2]. The authors describe that per-
sons with advanced dementia suffer from several symp-
toms that may need specialized palliative care, whether
it be at home, within a nursing home or in a hospital.
Given the significant lack of research in the field of
palliative care and dementia in Germany, it is impossible
to give evidence-based recommendations or to even de-
velop and evaluate interventions in order to improve
palliative care. Palliative care depends not only on cul-
tural, ethical and social prerequisites but also on legal
and financial conditions in different countries. Hence, it
is almost impossible to transfer research results, such as
those from the numerous, high-quality international
studies, to persons with dementia in Germany.
Neither in Germany nor internationally has any re-
search been conducted on palliative care in young onset
dementia (YOD), defined by an age at symptom onset
before 65 years, who live at home or in long term care
(LTC) facilities. Significant differences are expected be-
tween YOD compared to late-onset dementia (LOD),
such as lower somatic comorbidities in YOD, less frailty,
more behavioral and psychological symptoms, different
responses to psychopharmacological therapy, different
attitudes regarding end-of-life, and higher caregiver bur-
den [16]. However, these hypotheses have yet to be con-
firmed. Furthermore, most international studies have
focused on palliative care provision in LTC settings,
leaving little knowledge about palliative care of persons
with advanced dementia who receive care at home.
Aim and research questions
Therefore, the aims of the prospective cohort study EPY-
LOGE are:
1) To prospectively assess and describe advanced and
terminal stages of dementia patients who live in
LTC facilities or at home, regarding the following
criteria: a) symptom burden and symptom
management, b) health care utilization, c) palliative
care provision, d) quality of life and quality of
death, e) family caregivers’ satisfaction and needs
regarding care and decision making; f ) advance care
planning; g) validity and applicability of existing
advance directives for the situation of dementia.
2) To compare YOD and LOD: we hypothesize that in
advanced stages and at the end of life of YOD and
LOD patients, problems and unmet care needs exist
and differ between YOD and LOD.
3) To develop expert-consensus recommendations for
the improvement and implementation of strategies/
interventions regarding palliative care provision for
persons with advanced YOD and LOD.
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4) To communicate the results and the consecutive
recommendations both nationally and
internationally to the scientific community, to
relevant parties that are involved in patient care and
to patients and their families.
Methods
EPYLOGE is a prospective cohort study that includes a
baseline visit with the person suffering from dementia
and a family caregiver, quarterly phone calls with the
family caregivers and a follow-up visit with the family
caregiver after the person with dementia has died.
Subjects
Dyads of persons with advanced dementia, who live at
home or in LTC, and their family caregivers are identified
in multiple ways: 1) Through the Center of Cognitive Dis-
orders at the University Hospital of the Technical Univer-
sity of Munich: The family caregivers of persons with a
diagnosis of a neurodegenerative dementia, who have been
seen in the outpatient clinic since 2005, are contacted. If
the person with dementia fulfills the inclusion criteria, he
or she, and the corresponding family caregiver will be in-
vited to participate in the study; 2) Through a collabora-
tive network specialized in YOD in order to include a
sufficiently high number of persons with YOD (in spite of
its relatively low prevalence), institutions specialized in
YOD (i.e. nursing homes, support centers, research cen-
ters, etc.) are asked to establish contact with families of
persons with advanced YOD; 3) through LTC units in
urban and rural areas of Germany. Lack of informed con-
sent either from the person with dementia (or their legal
surrogate) or from their family caregiver is an exclusion
criterion.
Study design
EPYLOGE consists of four parts (see Fig. 1):
In part A (baseline-visit), palliative care issues in ad-
vanced dementia are analyzed and compared between
100 persons with YOD and 100 persons with LOD. Stud-
ies have shown that in Germany about 50% of persons
with advanced dementia are cared for at home [2]. Thus,
the objective is to include approximately 50 persons liv-
ing at home and 50 persons living in LTC in each group.
After the baseline visit, family caregivers are contacted
by phone every three months in order to briefly assess
changes of the living and care situation. The phone calls
are continued until the death of the person with demen-
tia or until the end of study. After the patient’s death as-
sessment B will be performed within 3 months at the
latest.
In part B (follow-up visit) palliative care issues at the
end of life are analyzed and compared between 50 de-
ceased persons with YOD and 50 deceased persons with
LOD identified by the phone calls described above. It is
anticipated that about 50% of the participants in part A
will die during the study period. In case this assumption
is not true and fewer participants die, or if deaths are
more common in specific subgroups (age, living situ-
ation), the groups in part B are completed with add-
itional bereaved families.
In part C, the results of part A and B will be discussed
in an expert round table that is scheduled for early 2020.
Expert consensus recommendations will concern strat-
egies and interventions in order to improve palliative
care in YOD and LOD.
In part D the expert consensus recommendations will
be disseminated.
Data collection
The first dyad comprised of the person with advanced
dementia and the family caregiver was included in Octo-
ber 2017. Patient recruitment is expected to last until
December 2019.
Instruments and measures
For part A - palliative care issues in advanced dementia:
a detailed assessment of the person with advanced de-
mentia and a standardized interview of the family care-
giver will be conducted at the baseline visit. If necessary,
additional information will be gathered from the nursing
staff. The instruments and measures of part A are de-
scribed in Table 1.
After part A, the respective family caregiver is perdio-
cially phoned every three months and changes regarding
living situation, care provision and comorbidities are
assessed. The post-mortem visit (part B) is arranged if
the person with dementia has died.
In part B - end-of life issues in advanced dementia:
standardized post mortem assessments are performed
with the family caregivers of 50 persons with YOD and
50 persons with LOD at a follow-up visit.
In part B, a standardized interview with the bereaved
family caregiver is performed less than three months
after the person with dementia has died. Instruments
and measures are described in Table 2.
Part C: After parts A and B are completed, an expert
round table discussion will be organized with experts
from the fields of dementia, palliative medicine and LTC
care, patient advocacy groups, dementia and palliative
care specialists, a medical ethicist, a jurist with a focus
on end-of-life topics, general practitioners providing
general outpatient palliative care representatives from
specialized outpatient palliative care services, from the
Health ministries as well as representatives from health/
nursing insurance companies. The results of parts A and
B will be reported and discussed in comparison to the
findings of international studies concerning the same
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topic. Expert consensus recommendations will be
drafted for strategies and interventions in order to im-
prove palliative care in YOD and LOD.
Part D: Dissemination: The results of the study and
of the expert consensus recommendations will be com-
municated nationally and internationally to the scientific
community in order to improve and adapt care guide-
lines as well as to give a basis and perspective for future
research projects. Furthermore, the results and rec-
ommendations will be communicated to the relevant
parties that are involved in patient care and support
(family and professional caregivers, palliative care spe-
cialists, physicians, memory clinics, patient advocacies,
LTC administrators, Ministries of Health, and health/
nursing insurance) in order to implement the recom-
mendations into daily care practice. Thirdly, the re-
sults and recommendations will be communicated to
persons with dementia and their families (through lay
press, lay people events, radio, internet, brochure) in
order to counsel and support their decision-making
processes and their communication with professional
caregivers and physicians.
Endpoints and sample size calculation
The scales and questionnaires in this study have been
used in several international studies investigating pallia-
tive care in dementia, including the Netherland’s Dutch
End of Life (DEOLD) study. A recent review has indi-
cated good psychometric properties in tests of palliative
care such as the Discomfort Scale for Dementia of the
Alzheimer Type (DS-DAT), which offers high internal
consistency [17].
Primary outcomes of EPYLOGE include patients’ qual-
ity of life, as measured by the Quality of Life in Late
Stage Dementia-Scale (QUALID) [18], and quality of
death, as measured by the Comfort Assessment of Dying
with Dementia-Scale (CAD-EOLD) [8]). These assess-
ments of quality of life and death will be compared be-
tween YOD and LOD patients. Secondary outcomes
include symptom burden and symptom management,
comfort measures, caregivers’ burden, satisfaction with
care and shared-decision making as well as health care
utilization. These secondary outcomes will be measured
by a variety of scales and questionnaires. The impact of
living situation (home/nursing home), gender, social sta-
tus and residence (rural vs. metropolitan area) on the
primary endpoints will be assessed.
Sample size calculation for the comparison of persons
with YOD and LOD was performed using the primary end-
points. Bonferroni adjustment for multiple comparisons
was utilized. The global significance level was set to 5%.
For part A, the comparison of persons with YOD and LOD
in advanced stages of dementia, the quality of life, as mea-
sured by the Quality of Life in Late Stage Dementia-Scale
(QUALID) [18]), was chosen as the primary endpoint. Scale
characteristics include: a near-normal distribution, a range
of 11 to 55 in which lower scores reflect higher quality of
life during the last seven days of life, a mean of 22.76, a
Fig. 1 EPYLOGE: Flow chart of study design and procedures
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standard deviation of 7.40, and a hypothesized clinically
meaningful difference of 5 points. A sample size of 86 per-
sons with dementia within each group will have 89% power
in detecting a difference in mean QUALID scores of 4, as-
suming that the common standard deviation is 7.4 and that
the two-sided independent samples t-test used will have
2.5% local significance. Assuming a drop-out rate of 14%,
at least 100 persons per group will be required, comprising
a total of 200 persons.
For part B, the comparison of persons with YOD and
LOD at end of life, the quality of death, as measured by
the Comfort Assessment of Dying with Dementia-Scale
(CAD-EOLD) [8]), was chosen as the primary endpoint.
Scale characteristics include: a near-normal distribution, a
range of 14 to 42 in which higher scores reflect better
comfort level, a mean of 31.4, a standard deviation of 5.9,
and a hypothesized clinically meaningful difference of 3
points. A sample size of 43 persons with dementia in each
group will have 80% power in detecting a difference in
mean CAD-EOLD scores of 4, assuming that the common
standard deviation is 5.9 and that the two-sided independ-
ent samples t-test used will include 2.5% local significance.
Assuming a drop-out rate of 14%, at least 50 recent cases
of deceased persons per group will be required for part B.
Statistical analysis
Primary endpoint analysis: The two groups (YOD and
LOD) will be compared with respect to both primary
endpoints. The two-sided independent samples t-test
will be used to test for differences in both primary
Table 1 Part A, baseline visit: instruments and measures
Assessments of the person with dementia
General data: Demographic data, living and care situation
Etiology of dementia, date of symptom onset, date of dementia diagnosis
Psychiatric and somatic comorbidities
Medical care: Pharmacotherapy, tube feeding, custodial measures
Cognitive status: Mini-Mental Status Examination (MMSE); Brief Language Assessment
Severity of dementia: Clinical Dementia Rating (CDR)
Activities of daily living: Barthel-Index
Pain: Pain Assessment in Advanced Dementia (PAINAD) Scale
Comfort: Discomfort Scale in Dementia (DS-DAT)
Patient suffering: Mini Suffering State Examination (MSSE)
Patient examination: Neurologic and somatic symptoms; psychopathology
Assesment of palliative care provision
Assessment of advance care planing (palliative care goals, advance directives, emergency orders)
Additional information about the person with dementia obtained from the family caregiver and, if necessary, from the nursing staff (if applicable)
Quality of life: Quality of Life in Late Stage Dementia (QUALID)
Symptom management: Modified version of End of Life in Dementia-Symptom Management/ EOLD-SM
Behavioral and psychological symptoms in dementia: Neuropsychiatric Inventory (NPI)
Suicidal ideation and behavior
Interviews of the family caregiver
General data: Demographic data, living situation
Wellbeing: WHO Five (WHO-5)
Depression: Beck Depression Inventory II (BDI II)
Strain: Caregiver Strain Index (CSI) (Robinson et al., 1983)
Burden: Burden Scale for Family Caregivers (BSFC)
Perception of care: Family Perception of Care Scale of St. Michael’s Hospice North Hampshire (FPCS) (https://www.stmichaelshospice.org.uk/
NHSS_family_perceptions_of_care_scale.pdf)
Satisfaction with care: Modified version of End of Life in Dementia-Satisfaction with Care (EOLD-SWC)
Open questions: Caregivers’ problems, challenges, barriers, needs, preferences regarding palliative care
Description of the LTC facility
If the person with dementia lives in an LTC facility, the administrator is asked to provide a detailed and standardized description of the facility,
infrastructure, organization, service provision, and palliative care provision.
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endpoints. The global significance level will be set to 5%.
The local significance level of each test (Bonferroni ad-
justment) will therefore be 2.5%.
Secondary endpoint analysis: Analyses of baseline data
and secondary endpoints will be performed using appro-
priate descriptive statistics and independent samples tests
for differences between the two study groups. All tests will
be two-sided with an exploratory significance level of 5%.
Ethical considerations, quality assurance and data protection
The study was approved by the Ethics Committee of the
Faculty of Medicine of the Technical University of Munich
(18. Aug. 2017; No. 281/17 S). A written informed consent
procedure with the patients and/or their legal surrogates
and the family caregivers is the basis for study participation.
The multi-disciplinary International Scientific Advisory
Board considers scientific and ethical issues. National
and international standards of quality assurance, par-
ticularly the Declaration of Helsinki Note for Guidance
on Good Clinical Practice (GCP) of the ICH
(ICH-GCP), 17.1.1997; (European Medicines Agency,
2002) are respected. Monitoring will be performed ac-
cording to a study-specific monitoring manual and
GCP-compliant monitoring standard operating proce-
dures. The study is conducted in compliance with Ger-
man data protection guidelines. Data are handled
confidentially. All information related to the study will
be kept archived for at least 10 years after completion
of the study in accordance with §13 Sec. 10 of the GCP
Regulations. The study is registered in ClinicalTrials.-
gov (NCT03364179; registered: 06. Dec 2017).
Discussion
To our knowledge, EPYLOGE is the first study that addresses
palliative care issues concerning dementia in Germany. A
unique feature of EPYLOGE is its focus on YOD and the
comparison between YOD and LOD. Some limitations of the
study need to be considered. Firstly, there may be a sampling
bias; most patients will be recruited through the memory
clinic of a university hospital. Patients who receive treatment
from a tertiary care center may not be representative for the
general population. However, we believe that recruitment
through LTC facilities - as done in most prior studies - gener-
ates an even larger sampling bias. That is because some LTC
facilities, presumably those who feel that they are deficient in
palliative care, may refuse to participate. Secondly, most of
the patient-related data will be collected by interviewing
family caregivers and nursing staff. These data may be less
reliable than desired; however, asking patients with ad-
vanced dementia directly about their condition, com-
plaints, etc. would potentially generate less reliable data
and is ethically problematic. Thirdly, the first visit might
raise awareness in the caregivers and perhaps in the nurs-
ing staff. As a consequence, palliative care may be im-
proved. Therefore, a bias should be considered at the post
mortem visit. Patients might have received better care at
the end of their life and experienced a better quality of
death than they would have if they had not been included
in part A of EPYLOGE.
In order to avoid wrong conclusions, one must consider
the limitations of the study during the interpretation and
dissemination of results. EPYLOGE aims to address these
limitations throughout the study, allowing for stronger in-
terpretations of results. In summary, EPYLOGE will serve
as a basis for the improvement of palliative care in demen-
tia. EPYLOGE also aims to implement strategies and inter-
ventions regarding palliative care provision for persons with
advanced YOD and LOD. Furthermore, EPYLOGE is a
cornerstone of future research in the field of palliative care
in dementia.
Table 2 Part B, follow-up visit with family caregiver post-mortem: instruments and measures
Interviews of the family caregiver
Symptoms, treatment and care before death and circumstances of death as reported by the caregiver and identified by retrospective evaluation
of medical and care files; evaluation if advance directives have been applied.
Caregiver satisfaction with care: End of Life in Dementia-Satisfaction with Care (EOLD-SWC) (Volicer L et al., [8])
Burden: Modified version of Burden Scale for Family Caregivers (BSFC)
Patient suffering: Mini Suffering State Examination (MSSE)
Quality of life: Modified version of Quality of Life in Late Stage Dementia (QUALID)
Symptom management: End of Life in Dementia-Symptom Management (EOLD-SM) (Volicer L et al., [8])
Persons with dementias comfort in dying: Comfort Assessment of Dying with Dementia (CAD-EOLD) (Volicer L et al., [8])
Caregiver wellbeing: WHO five (WHO-5)
Caregiver depression: Beck Depression Inventory II (BDI II)
Open questions: Caregivers’ problems, challenges, barriers, needs, preferences regarding end-of-life care.
Description - LTC
If the person with dementia lives in an LTC facility, the administrator is asked to provide a detailed and standardized description of the facility,
infrastructure, organization, service provision, and palliative care provision.
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